Valuation: Jade Biosciences, Inc.

Market Cap 894M 801M 737M 667M 1.25B 84.9B 1.27B 8.78B 3.53B 44.66B 3.36B 3.28B 141B P/E 2026 *
-4.81x
P/E 2027 * -4.9x
Enterprise Value 548M 491M 452M 409M 765M 52.08B 780M 5.39B 2.16B 27.4B 2.06B 2.01B 86.4B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.21%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Jade Biosciences, Inc.

1 day-1.26%
1 week-3.63%
Current month+0.07%
1 month+0.07%
3 months-29.70%
6 months-42.38%
Current year-8.88%
1 week 13.83
Extreme 13.83
15.06
1 month 12.85
Extreme 12.8465
15.44
Current year 12.45
Extreme 12.45
28
1 year 8.36
Extreme 8.36
28
3 years 6.56
Extreme 6.565
28
5 years 6.56
Extreme 6.565
28
10 years 6.56
Extreme 6.565
28
Manager TitleAgeSince
Chief Executive Officer 50 28/04/2025
Director of Finance/CFO 38 14/07/2025
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Director/Board Member 50 28/04/2025
Director/Board Member 42 28/04/2025
Chairman 57 28/04/2025
Date Insider Type Main position Quantity % Market Cap. Importance
6/25/26 A Free

Director

47,675 0.0966%
2/12/26 A Free

General Counsel

196,875 0.4280%
2/12/26 A Free

Chief Technology Officer

288,750 0.6277%
Change 5-day change 1-year change 3-year change Capi.($)
-1.26%-3.63%+42.74% - 894M
-0.62%-1.87%+46.31%+56.99% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+50.90% 44.06B
-0.33%-1.93%+20.15%+98.45% 42.11B
+0.55%+2.31%+224.97%+942.56% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-42.03%+373.03% 24.7B
Average +0.18%+6.42%+47.35%+206.32% 39.52B
Weighted average by Cap. +0.17%+5.42%+48.49%+186.13%

Financials

2026 *2027 *
Net sales - -
Net income -204M -183M -168M -152M -285M -19.39B -290M -2.01B -805M -10.2B -766M -750M -32.17B -231M -207M -190M -173M -322M -21.95B -329M -2.27B -912M -11.54B -867M -849M -36.41B
Net Debt -346M -310M -285M -258M -482M -32.82B -491M -3.4B -1.36B -17.27B -1.3B -1.27B -54.45B -354M -317M -291M -264M -494M -33.59B -503M -3.47B -1.39B -17.67B -1.33B -1.3B -55.71B
Projected Income Statement - Annual - Jade Biosciences, Inc.
Logo Jade Biosciences, Inc.
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
Employees
55
Date Price Change Volume
30/10/26 $14.06 -1.26% 682,307
29/10/26 $14.24 -2.40% 896,089
28/10/26 $14.59 -1.02% 671,516
27/10/26 $14.74 +1.66% 652,901
26/10/26 $14.50 -0.62% 477,455
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Jade Biosciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
14.06USD
Average target price
50.12USD
Spread / Average Target
+256.51%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Jade Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. JBIO Stock